Edwards Lifesciences EW
Edwards Lifesciences is a medical device company that designs and sells heart valves and hemodynamic monitoring products, being a leader in transcatheter aortic valve replacement (TAVR). Edwards Lifesciences shows solid financial health (8.82) with net cash and operating margins of 29.84%, but its valuation is demanding (P/E 51.36) and earnings growth is negative (-25.4%). The expansion of Medicare coverage for TAVR is a key catalyst that expands its market and strengthens its medium-term growth prospects.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Edwards Lifesciences is a medical device company that designs and sells heart valves and hemodynamic monitoring products, being a leader in transcatheter aortic valve replacement (TAVR). Edwards Lifesciences shows solid financial health (8.82) with net cash and operating margins of 29.84%, but its valuation is demanding (P/E 51.36) and earnings growth is negative (-25.4%). The expansion of Medicare coverage for TAVR is a key catalyst that expands its market and strengthens its medium-term growth prospects.
Score by category
| Category | Score |
|---|---|
| Financial health | 8.8 |
| Quality / Moat | 7.2 |
| Valuation | 3.6 |
| Growth | 4.7 |
| Dividend | 1.5 |
| Momentum | 7.3 |
| Risk & Context | 7.1 |
OVERALL SCORE: 5.9/10
Context and risks
The macro context (rates, oil, geopolitics) does not materially affect Edwards' medical devices business. The company has net cash, so the impact of rates is negligible. The CMS regulatory risk is already reflected in the positive news of coverage expansion.
News considered in the analysis
- CMS expands TAVR Medicare coverage to asymptomatic patients — Expansión material del mercado TAVR al cubrir a pacientes asintomáticos, ampliando la base de pacientes elegibles y el potencial de ingresos.
- Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead — La expansión de TAVR y la oportunidad de $2B en TMTT (terapia transcatéter mitral y tricúspide) refuerzan las perspectivas de crecimiento a medio plazo.
- Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion — Análisis positivo post-expansión de Medicare, señalando que la valoración es razonable tras el movimiento.
- How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions — Cobertura de análisis sobre el impacto de la expansión de TAVR y las ambiciones en válvulas transcatéter.
- Is Edwards Lifesciences Stock Underperforming the Dow? — Comparativa de rendimiento sin información nueva sobre los fundamentales de la empresa.
Verdict: Hold, with a positive bias due to the TAVR expansion regulatory catalyst, but watch the demanding valuation and the evolution of earnings growth.
Main risk: The main risk is the demanding valuation (P/E 51.36) that leaves little room for error: if earnings growth does not recover after the -25.4% decline, the multiple could compress significantly.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →